Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387026333> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4387026333 endingPage "AB156" @default.
- W4387026333 startingPage "AB156" @default.
- W4387026333 abstract "Background: Itch is a major complaint among patients with seborrheic dermatitis (SD). Roflumilast is a selective, nonsteroidal, highly potent phosphodiesterase-4 inhibitor under investigation as a once-daily foam for treatment of SD. This phase 3 randomized, parallel-group, double-blind, vehicle-controlled trial (NCT04973228) was conducted in patients 2:9 years old with at least moderate SD affecting scalp and/or non-scalp areas. Patients were randomized 2:1 to apply once-daily roflumilast foam 0.3% (n=304) or vehicle (n=153) for 8 weeks. The primary efficacy endpoint was Investigator Global Assessment (IGA) success (IGA of Clear or Almost Clear plus 2:2-grade improvement from baseline) at Week 8. Secondary efficacy endpoints included Worst Itch Numeric Rating Scale (WI-NRS), which was completed daily by patients. Safety and local tolerability were also evaluated. Overall, significantly more roflumilast-treated patients than vehicle-treated patients achieved IGA success (80.1% vs. 59.2%; P<0.0001) and IGA status of Clear (50.7% vs. 28.2%; P<0.0001) at Week 8. Significantly greater percentages of roflumilast- than vehicle-treated patients had 2:4-point improvement on WI-NRS at Weeks 2 (32.6% vs. 15.6%; P=0.0019), 4 (47.9% vs. 30.4%; P=0.0014), and 8 (63.6% vs. 42.3%; P=0.0002). Greater improvement in itch was observed among roflumilast-treated patients as early as 48 hours after the first application (mean percent change from baseline: -27.87% vs. -13.11%; nominal P=0.0024). Local tolerability and safety were favorable. Once-daily roflumilast foam provided improvement across multiple efficacy endpoints including rapid itch improvement, while demonstrating favorable safety and tolerability." @default.
- W4387026333 created "2023-09-26" @default.
- W4387026333 creator A5004423217 @default.
- W4387026333 creator A5006526834 @default.
- W4387026333 creator A5008286260 @default.
- W4387026333 creator A5011094833 @default.
- W4387026333 creator A5022873173 @default.
- W4387026333 creator A5028212145 @default.
- W4387026333 creator A5032745718 @default.
- W4387026333 creator A5063690905 @default.
- W4387026333 creator A5066616903 @default.
- W4387026333 creator A5080237247 @default.
- W4387026333 creator A5085051271 @default.
- W4387026333 date "2023-09-01" @default.
- W4387026333 modified "2023-09-26" @default.
- W4387026333 title "42835 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: Assessment of Pruritus" @default.
- W4387026333 doi "https://doi.org/10.1016/j.jaad.2023.07.626" @default.
- W4387026333 hasPublicationYear "2023" @default.
- W4387026333 type Work @default.
- W4387026333 citedByCount "0" @default.
- W4387026333 crossrefType "journal-article" @default.
- W4387026333 hasAuthorship W4387026333A5004423217 @default.
- W4387026333 hasAuthorship W4387026333A5006526834 @default.
- W4387026333 hasAuthorship W4387026333A5008286260 @default.
- W4387026333 hasAuthorship W4387026333A5011094833 @default.
- W4387026333 hasAuthorship W4387026333A5022873173 @default.
- W4387026333 hasAuthorship W4387026333A5028212145 @default.
- W4387026333 hasAuthorship W4387026333A5032745718 @default.
- W4387026333 hasAuthorship W4387026333A5063690905 @default.
- W4387026333 hasAuthorship W4387026333A5066616903 @default.
- W4387026333 hasAuthorship W4387026333A5080237247 @default.
- W4387026333 hasAuthorship W4387026333A5085051271 @default.
- W4387026333 hasConcept C126322002 @default.
- W4387026333 hasConcept C16005928 @default.
- W4387026333 hasConcept C168563851 @default.
- W4387026333 hasConcept C197934379 @default.
- W4387026333 hasConcept C203092338 @default.
- W4387026333 hasConcept C204243189 @default.
- W4387026333 hasConcept C2776780178 @default.
- W4387026333 hasConcept C2778375690 @default.
- W4387026333 hasConcept C2778515351 @default.
- W4387026333 hasConcept C2778926808 @default.
- W4387026333 hasConcept C71924100 @default.
- W4387026333 hasConcept C90924648 @default.
- W4387026333 hasConceptScore W4387026333C126322002 @default.
- W4387026333 hasConceptScore W4387026333C16005928 @default.
- W4387026333 hasConceptScore W4387026333C168563851 @default.
- W4387026333 hasConceptScore W4387026333C197934379 @default.
- W4387026333 hasConceptScore W4387026333C203092338 @default.
- W4387026333 hasConceptScore W4387026333C204243189 @default.
- W4387026333 hasConceptScore W4387026333C2776780178 @default.
- W4387026333 hasConceptScore W4387026333C2778375690 @default.
- W4387026333 hasConceptScore W4387026333C2778515351 @default.
- W4387026333 hasConceptScore W4387026333C2778926808 @default.
- W4387026333 hasConceptScore W4387026333C71924100 @default.
- W4387026333 hasConceptScore W4387026333C90924648 @default.
- W4387026333 hasIssue "3" @default.
- W4387026333 hasLocation W43870263331 @default.
- W4387026333 hasOpenAccess W4387026333 @default.
- W4387026333 hasPrimaryLocation W43870263331 @default.
- W4387026333 hasRelatedWork W2053485995 @default.
- W4387026333 hasRelatedWork W2113780394 @default.
- W4387026333 hasRelatedWork W2154883587 @default.
- W4387026333 hasRelatedWork W2414338203 @default.
- W4387026333 hasRelatedWork W2584850773 @default.
- W4387026333 hasRelatedWork W2998663103 @default.
- W4387026333 hasRelatedWork W3212096909 @default.
- W4387026333 hasRelatedWork W4244069386 @default.
- W4387026333 hasRelatedWork W4304479650 @default.
- W4387026333 hasRelatedWork W4384922324 @default.
- W4387026333 hasVolume "89" @default.
- W4387026333 isParatext "false" @default.
- W4387026333 isRetracted "false" @default.
- W4387026333 workType "article" @default.